English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Attempts of establishing vaccines against cancers are in process of becoming authentic in future due to its successful clinical trials. But, there are problems in assessing the prognosis of the diseases due to the weakness and specificity of tumor associated antigens in stimulating an effective immune response. A surplus combination of immunotherapeutic cancer strategies and appropriate checkpoint inhibitors, becomes a promising area for successful cancer disease control. This article summarizes the understanding of tumor antigens (specific or associated) in head and neck squamous cell carcinoma, which allow some space with a positive and hopeful view of the future.

Immunotherapeutic Modalities in the Treatment of Head & Neck Squamous Cell Carcinoma